These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 8360131)

  • 1. Once- versus twice-daily amikacin regimen: efficacy and safety in systemic gram-negative infections. Scandinavian Amikacin Once Daily Study Group.
    Maller R; Ahrne H; Holmen C; Lausen I; Nilsson LE; Smedjegård J
    J Antimicrob Chemother; 1993 Jun; 31(6):939-48. PubMed ID: 8360131
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of amikacin in systemic infections when given as a single daily dose or in two divided doses. Scandinavian Amikacin Once Daily Study Group.
    Maller R; Ahrne H; Eilard T; Eriksson I; Lausen I
    J Antimicrob Chemother; 1991 May; 27 Suppl C():121-8. PubMed ID: 1856141
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative kinetics and efficacy of amikacin administered once or twice daily in the treatment of systemic gram-negative infections.
    Giamarellou H; Yiallouros K; Petrikkos G; Moschovakis E; Vavouraki E; Voutsinas D; Sfikakis P
    J Antimicrob Chemother; 1991 May; 27 Suppl C():73-9. PubMed ID: 1906864
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the efficacy and safety of amikacin once or twice-a-day in the treatment of severe gram-negative infections in the elderly.
    Vanhaeverbeek M; Siska G; Douchamps J; Herchuelz A
    Int J Clin Pharmacol Ther Toxicol; 1993 Mar; 31(3):153-6. PubMed ID: 8468114
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The efficacy and safety of isepamicin and ceftazidime compared with amikacin and ceftazidime in acute lower respiratory tract infection.
    Colardyn F
    J Chemother; 1995 Jun; 7 Suppl 2():129-35. PubMed ID: 8622101
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospective randomized study of once-daily versus twice-daily amikacin regimens in patients with systemic infections.
    Karachalios GN; Houpas P; Tziviskou E; Papalimneou V; Georgiou A; Karachaliou I; Halkiadaki D
    Int J Clin Pharmacol Ther; 1998 Oct; 36(10):561-4. PubMed ID: 9799062
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Isepamicin once daily plus ceftriaxone versus amikacin plus ceftriaxone in febrile neutropenic patients.
    Herbrecht R; Blaise D; Espinouse D; Leblond V; Sadoun A; Sauvage C; Cordonnier C; Minozzi C
    J Chemother; 1995 Jun; 7 Suppl 2():103-10. PubMed ID: 8622099
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The efficacy and toxicity of two dosing-regimens of amikacin in neonates with sepsis.
    Abdel-Hady E; El Hamamsy M; Hedaya M; Awad H
    J Clin Pharm Ther; 2011 Feb; 36(1):45-52. PubMed ID: 21198719
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the efficacy and safety of isepamicin compared with amikacin in the treatment of nosocomial pneumonia and septicaemia.
    Beaucaire G
    J Chemother; 1995 Jun; 7 Suppl 2():165-73. PubMed ID: 8622107
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum concentrations and safety of single daily dosing of amikacin in children undergoing bone marrow transplantation.
    Viscoli C; Dudley M; Ferrea G; Boni L; Castagnola E; Barretta MA; Lanino E; Loy A; Moroni C; Somenzi M
    J Antimicrob Chemother; 1991 May; 27 Suppl C():113-20. PubMed ID: 1856140
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the efficacy and safety of isepamicin and amikacin in the treatment of skin and skin structure infections.
    Rodriguez-Noriega E; Esparza-Ahumada S; Morfin-Otero R
    J Chemother; 1995 Jun; 7 Suppl 2():155-60. PubMed ID: 8622105
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the efficacy and safety of isepamicin and amikacin in the treatment of acute lower respiratory tract infections caused by gram-negative organisms.
    Covi M; Velluti G
    J Chemother; 1995 Jun; 7 Suppl 2():137-42. PubMed ID: 8622102
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nebulized Versus IV Amikacin as Adjunctive Antibiotic for Hospital and Ventilator-Acquired Pneumonia Postcardiac Surgeries: A Randomized Controlled Trial.
    Hassan NA; Awdallah FF; Abbassi MM; Sabry NA
    Crit Care Med; 2018 Jan; 46(1):45-52. PubMed ID: 28857848
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single daily dose amikacin in paediatric patients with severe gram-negative infections.
    Trujillo H; Robledo J; Robledo C; Espinal D; Garces G; Mejia J; Restrepo C; Restrepo F; Mejia de Rodriguez GI; Tamayo de Guitierrez MC
    J Antimicrob Chemother; 1991 May; 27 Suppl C():141-7. PubMed ID: 1856143
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The pharmacokinetic of amikacin in critically ill adult and paediatric patients: comparison of once- versus twice-daily dosing regimens.
    Marik PE; Havlik I; Monteagudo FS; Lipman J
    J Antimicrob Chemother; 1991 May; 27 Suppl C():81-9. PubMed ID: 1856148
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A study of amikacin given once versus twice daily in serious infections.
    Maller R; Isaksson B; Nilsson L; Sörén L
    J Antimicrob Chemother; 1988 Jul; 22(1):75-9. PubMed ID: 3170393
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics and tolerability of amikacin administered as BAY41-6551 aerosol in mechanically ventilated patients with gram-negative pneumonia and acute renal failure.
    Luyt CE; Eldon MA; Stass H; Gribben D; Corkery K; Chastre J
    J Aerosol Med Pulm Drug Deliv; 2011 Aug; 24(4):183-90. PubMed ID: 21361783
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical and pharmacokinetic study of a single daily dose of amikacin in paediatric patients with severe gram-negative infections.
    Kafetzis DA; Sianidou L; Vlachos E; Davros J; Baïramis T; Papandreou Y; Paraskaki E; Scouroliakou M; Hadzis A; Papadatos J
    J Antimicrob Chemother; 1991 May; 27 Suppl C():105-12. PubMed ID: 1906861
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A prospective, controlled, randomized, non-blind, comparative study of the efficacy and safety of a once daily high dose of ceftriaxone plus ciprofloxacin versus thrice daily ceftazidime plus amikacin in empirical therapy for febrile neutropenic patients.
    Metallidis S; Kollaras P; Giannakakis T; Seitanidis B; Kordosis T; Nikolaidis J; Hatzitolios A; Nikolaidis P
    Eur J Intern Med; 2008 Dec; 19(8):619-24. PubMed ID: 19046729
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of once-daily amikacin in combination with ceftazidime in critically ill adults with severe gram-negative infections.
    Fayed DF; Dahmash NS; al-Zeer AH; Shibl AM; Huraib SO; Abu-Aisha H
    J Chemother; 1996 Dec; 8(6):457-64. PubMed ID: 8981187
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.